id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2015-D-3517-0021,FDA,FDA-2015-D-3517,"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry; Availability",Notice,Notice of Availability,2023-12-07T05:00:00Z,2023,12,2023-12-07T05:00:00Z,,2023-12-07T14:38:58Z,2023-26886,0,0,09000064863099ff
FDA-2015-D-3517-0022,FDA,FDA-2015-D-3517,"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Draft Guidance for Industry",Other,Guidance,2023-12-07T05:00:00Z,2023,12,2023-12-07T05:00:00Z,2024-01-09T04:59:59Z,2025-01-07T21:45:09Z,,0,0,090000648630bbb2